This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Pathogenesis

Authoring team

Aplastic anaemia may result from defects in haemopoietic stem cells or in the marrow micro-environment. The precise mechanism is often unknown but the ability to correct the defect by bone marrow transplantation suggests that the fault often lies in the stem cells.

Many individuals show evidence of an immune-mediated suppression of haematopoiesis. Cellular mechanisms seem most important. In some individuals T cells produce in vitro suppression of autologous marrow stem cells. Humoral mechanisms may be involved since antibodies to stem cells have been found.

Additional support for the importance of immunosuppression derives from transplant studies. Only 50% of those treated by transplantation from an identical twin donor recover normal haematopoiesis; preceding the second transplant with intensive immunosuppression using cyclophosphamide then facilitates full recovery. Additionally, 50% of patients treated with anti-thymocyte globulin (ATG) or anti - lymphocyte globulin (ALG) recover without marrow transplantation.

Failure of a 'committed' cell may result in decreased cell production or renewal, resulting in deficiencies such as pure red cell aplasia.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.